

03-27-2003

HEET



To the Honorable Commissione

102401671

... record the attached original documents or copy thereof.

1. Name of conveying party(ies):
Novartis Finance Corporation

3-24-03

2. Name and address of receiving party(ies)

Name: Syngenta Investment Corporation

Internal Address:

Additional name(s) of conveying party(ies) attached? Yes No

3. Nature of conveyance:

- Assignment Merger
- Security Agreement Change of Name
- Other _____

Street Address: 2200 Concord Pike

City: Wilmington State: DE ZIP: 19803

Execution Dates: January 29, 2003

Additional name(s) & address(es) attached? Yes No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s)

09/196,019 and 09/730,917

B. Patent No.(s)

5,767,373; 5,939,602; 6,023,012; 6,084,155; 6,177,245;
6,282,837; 6,288,306; 6,307,129; and 6,308,458

Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Larry W. Stults

Internal Address: Syngenta Biotechnology, Inc.
Patent Department

Street Address: 3054 Cornwallis Road

City: Research Triangle Park State: NC ZIP: 27709

6. Total number of applications and patents involved: 11

7. Total fee (37 CFR 3.41) \$ 440.00

Please charge Applicant's Credit Card. A Credit Card Payment Form is enclosed.

8. Deposit account number:

50-1744 (in the name of Syngenta Biotechnology, Inc.)

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Mary Kakefuda

Name of Person Signing
Reg. No. 39,245

Mary Kakefuda
Signature

3/19/03
Date

Total number of pages including cover sheet, attachments, and document: 3

Mail documents to be recorded with required cover sheet information to:

Box: Assignment, Commissioner for Patents
Washington, D.C. 20231

03/26/2003 LMUELLER 00000030 09196019

01 FC:8021

440.00 DP

ASSIGNMENT

Whereas, Novartis Finance Corporation, 608 Fifth Avenue, New York, NY 10020, a corporation of New York, is the assignee and legal owner of the entire right, title and interest in each of United States Patents 5,767,373, 5,939,602, 6,023,012, 6,084,155, 6,177,245, 6,282,837, 6,288,306, 6,307,129 and 6,308,458, abandoned United States Patent Application Nos. 08/261,198, 09/038,878, 09/059,164, 09/198,794 and 09/451,650 and pending United States Patent Application Nos. 09/196,019 and 09/730,917; and


Whereas, in accordance with a resolution of its Board of Directors made on October 31, 2000, Novartis Finance Corporation wishes to assign its entire interest in each of United States Patents 5,767,373, 5,939,602, 6,023,012, 6,084,155, 6,177,245, 6,282,837, 6,288,306, 6,307,129 and 6,308,458, abandoned United States Patent Application Nos. 08/261,198, 09/038,878, 09/059,164, 09/198,794 and 09/451,650 and pending United States Patent Application Nos. 09/196,019 and 09/730,917 to Syngenta Investment Corporation, 2200 Concord Pike, Wilmington, DE 19803, a corporation of Delaware, and said Syngenta Investment Corporation wishes to acquire Novartis Finance Corporation's interest in said patents and abandoned and pending patent applications.

Now, therefore, Novartis Finance Corporation hereby assigns to Syngenta Investment Corporation and its successors and assigns its entire right, title and interest in (1) (a) each of United States Patents 5,767,373, 5,939,602, 6,023,012, 6,084,155, 6,177,245, 6,282,837, 6,288,306, 6,307,129 and 6,308,458, (b) any and all applications for reissues of said patents, (c) any and all reissues of said patents that may be issued and/or granted, (d) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (e) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), (2) abandoned United States Patent Application Nos. 08/261,198, 09/038,878, 09/059,164, 09/198,794 and 09/451,650 and (3) (a) United States Patent Application Nos. 09/196,019 and 09/730,917, (b) any and all continuations and divisions of said application (including further continuations and divisions such as, but not limited to, continuations and divisions of continuations), (c) any and all patents that may be issued and/or granted on all of said applications, (d) any and all applications for reissues of said patents, (e) any and all reissues of said patents that may be issued and/or granted, (f) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (g) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), including, in the case of all patents (including reissue patents) within the scopes of (1) and (3), the right to sue, and to obtain damages, for past infringement, said right, title and interest conveyed herein by Novartis Finance Corporation to Syngenta Investment Corporation constituting the entire right, title and interest in said patents (including reissue patents), abandoned applications, pending application, extensions and reexamination certificates.

In witness whereof, Novartis Finance Corporation has caused this Assignment to be signed by its duly authorized corporate officer.

Signed this 29th day of January 2003.

Novartis Finance Corporation



Wayne P. Merkelson
Vice-President